1128-71-8

Basic information

• Product Name: 4-(1,3-Oxazol-5-yl)phenol
• Synonyms: 4-(1,3-Oxazol-5-yl)phenol;4-(5-Oxazolyl)Phenol;4-(Oxazol-5-yl)phenol
• CAS NO: 1128-71-8
• Molecular Formula: C₉H₇NO₂
• Molecular Weight: 161.159
• Product Categories: Alcohols and Derivatives
• Mol File: 1128-71-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 317.6°C at 760 mmHg
• Flash Point: 145.9°C
• Appearance: /
• Density: 1.247g/cm³
• Vapor Pressure: 0.000205mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(1,3-Oxazol-5-yl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,3-Oxazol-5-yl)phenol(1128-71-8)
• EPA Substance Registry System: 4-(1,3-Oxazol-5-yl)phenol(1128-71-8)

Safety Data

• Hazardous Substances Data: 1128-71-8(Hazardous Substances Data)

Usage

General Description

4-(1,3-oxazol-5-yl)phenol is a chemical compound with the molecular formula C10H7NO2. It is a phenolic compound that contains an oxazole ring and a hydroxyl group. This chemical is typically used in organic synthesis and medicinal chemistry. It has been studied for its potential biological activities, including its antioxidant and antimicrobial properties. The compound has also been investigated for its potential use in the development of new pharmaceuticals and agrochemicals. Additionally, it may have potential applications in the field of materials science and nanotechnology. Overall, 4-(1,3-oxazol-5-yl)phenol is a versatile compound with a range of potential uses in various industries.

InChI:InChI=1/C9H7NO2/c11-8-3-1-7(2-4-8)9-5-10-6-12-9/h1-6,11H

Upstream product

• 1011-51-4 5-(4-methoxyphenyl)-1,3-oxazole 
• 288-42-6 oxazol 
• 106-41-2 4-bromo-phenol 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 53242-58-3 2-hydroxy-5-oxazol-5-yl-benzoic acid 

Relevant articles and documents

Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells

Targeted therapies for ER+/PR+ and HER2-amplified breast cancers have improved patient survival, but there are no therapies for triple negative breast cancers (TNBC) that lack expression of estrogen and progesterone receptors (ER/PR), or amplification or

Mild palladium-catalyzed regioselective direct arylation of azoles promoted by tetrabutylammonium acetate

A mild, general, and convenient palladium-catalyzed direct arylation of the 5-position of azoles with aryl bromides, efficiently promoted by tetrabutylammonium acetate, is described. 1-Methylpyrazole, oxazole, and thiazole reacted at 70°C in N,N-dimethyla

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acq